Background-Group X secretory phospholipase A 2 (sPLA 2 -X) has the most potent hydrolyzing activity toward phosphatidylcholine and elicits a marked release of arachidonic acid among several types of sPLA 2 . sPLA 2 -X is expressed in neutrophils, but its pathogenic role remains unclear. Methods and Results-We generated mice that lack sPLA 2 -X and studied their response to myocardial ischemia/reperfusion.
P hospholipases A 2 (PLA 2 s) are ubiquitous enzymes that hydrolyze the sn-2-acyl bond of phospholipids of cell membrane and lipoproteins and yield free fatty acids and lysophospholipids, precursors of various bioactive lipid mediators. [1] [2] [3] [4] Among free fatty acids, arachidonic acid (AA) is known as a precursor of eicosanoids that include prostaglandins, thromboxanes, and leukotrienes. [1] [2] [3] [4] At present, a number of PLA 2 s have been identified and classified into different families on the basis of their biochemical features and primary structures. Among them, secretory PLA 2 s (sPLA 2 s) are the secreted enzymes that possess several characteristic features, including a low molecular mass (13 to 18 kDa) and an absolute catalytic requirement for millimolar concentrations of Ca 2ϩ . [1] [2] [3] [4] [5] [6] [7] On the basis of the primary structures, human sPLA 2 s are now classified into 9 different groups (IB, IIA, IID, IIE, IIF, III, V, X, and XII). 1-7 sPLA 2 s exhibit tissue-and species-specific expression, which suggests that their cellular functions may differ. [1] [2] [3] 6, 8, 9 The recently cloned group X sPLA 2 (sPLA 2 -X), one of sPLA 2 s, possesses several characteristics distinct from other sPLA 2 s. 1-3,7,10 -12 Among the human sPLA 2 s, sPLA 2 -X has the most potent hydrolyzing activity toward phosphatidylcholine and elicits a marked release of AA from various intact cell membranes independently of cytosolic PLA 2 (cPLA 2 ). 10 -12 sPLA 2 -X is expressed in various inflammatory cells including neutrophils. 11, 13 However, the pathogenic role of sPLA 2 -X in neutrophil-related tissue injury remains unclear.
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We have previously shown that plasma levels of sPLA 2 -IIA are a strong predictor of coronary artery disease. 14 
During
myocardial ischemia/reperfusion, neutrophils migrate through the endothelium of myocardial vascular beds to extravascular space where the activated neutrophils release a barrage of cytotoxic products, such as reactive oxygen species and proteolytic enzymes, leading to myocardial injury. 15, 16 AA and its lipid metabolites mediated by PLA 2 in neutrophils themselves have been shown to contribute to the activation of neutrophils during myocardial ischemia/reperfusion. [17] [18] [19] Furthermore, the secreted sPLA 2 -X is capable of exerting cytotoxic activities on neighboring cells. 20 In the present study, we generated mice that lack sPLA 2 -X (sPLA 2 -X Ϫ/Ϫ mice) and studied their response to myocardial ischemia/reperfusion to investigate the potential role of sPLA 2 -X in myocardial ischemia/reperfusion injury.
Methods

Materials
LY374388 ([3-aminooxalyl-1-benzyl-2-ethyl-6-methyl-1H-indol-4-yloxy]-acetic acid methyl ester) is a prodrug of LY329722 (sodium [3-aminooxalyl-1-benzyl-2-ethyl-6-methyl-1H-indol-4-yloxy]-acetic acid), an inhibitor of sPLA 2 activity. For details, see the online-only Data Supplement.
Mice
The experimental protocol was approved by the University of Yamanashi Animal Care and Use Committee, and procedures were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (1996) . All sPLA 2 -X Ϫ/Ϫ mice analyzed were male and from F 13 to F 15 , and Figure 1. Myocardial infarct size and echocardiography. A, Comparison of myocardial infarct size between sPLA 2 -X ϩ/ϩ mice (black bars) and sPLA 2 -X Ϫ/Ϫ mice (white bars). The right panel shows representative photomicrographs of sections of LV from sPLA 2 -X ϩ/ϩ and sPLA 2 -X Ϫ/Ϫ mice after 1 hour of occlusion of the left anterior descending artery followed by 24 hours of reperfusion. Viable myocardium is stained red by the reaction with 2-3-5-triphenyl tetrazolium chloride. The infarct area, which is demarcated, appears pale because of lack of 2-3-5-triphenyl tetrazolium chloride staining. The left panel summarizes data indicating the area at risk as a percentage of LV mass (AAR/LV), infarct size (IS) as a percentage of area at risk (IS/AAR), and IS as a percentage of LV mass (IS/LV) in sPLA 2 -X ϩ/ϩ and sPLA 2 -X Ϫ/Ϫ mice (nϭ12 in each genotype). *PϽ0.01. B, In vivo transthoracic echocardiography at baseline and after 1 hour of ischemia followed by 24 hours of reperfusion. M-mode images were obtained for measurement of LV end-diastolic and end-systolic dimensions (LVDd and LVDs). FS was calculated as described in the online-only Data Supplement (nϭ10 in each genotype). Black bars indicate sPLA 2 -X ϩ/ϩ mice, and white bars indicate sPLA 2 -X Ϫ/Ϫ mice. †PϽ0.05 compared with the respective baselines. *PϽ0.01. C, Bone marrow transplant experiments. The irradiated recipient sPLA 2 -X ϩ/ϩ mice were transplanted with bone marrow cells from sPLA 2 -X ϩ/ϩ mice (ϩ/ϩ3ϩ/ϩ, black bars) or sPLA 2 -X Ϫ/Ϫ mice (Ϫ/Ϫ3ϩ/ϩ, white bars) and subjected to the myocardial ischemia/reperfusion experiment in vivo at 6 weeks after bone marrow transplantation (nϭ5 in each experiment). *PϽ0.05. D, Langendorff experiment. No difference was found in infarct size/LV between sPLA 2 -X ϩ/ϩ (black bar) and sPLA 2 -X Ϫ/Ϫ mice (white bar) (nϭ10 in each genotype).
the littermate sPLA 2 -X ϩ/ϩ male mice were used as controls. For details, see the online-only Data Supplement.
Construction of Targeting Vector and Generation of sPLA 2 -X-Deficient Mice
The mouse sPLA 2 -X gene was cloned from a 129 SVJ genomic library (Stratagene) with the use of oligo DNA, with 5Ј-tacacctgtcactctcctatgtgtg-3Ј of mouse sPLA 2 -X as a probe. The 2.8-kb XbaI-AccII and 3.0-kb PstI-PstI genomic fragments derived from the isolated clone were used for the construction of the targeting vector ( Figure I 
Bone Marrow Transplantation Experiment
The sPLA 2 -X ϩ/ϩ mice (7 to 8 weeks of age) were lethally irradiated with 8 Gy. Immediately after irradiation, 5ϫ10 6 bone marrow cells Figure 2 . Expression of sPLA 2 -X in sPLA 2 -X ϩ/ϩ mice. A, sPLA 2 -X mRNA and protein expression in various tissues from sPLA 2 -X ϩ/ϩ mice (lung at the right end was from sPLA 2 -X Ϫ/Ϫ mice). Upper lanes (mRNA) show agarose gel electrophoresis of the amplified polymerase chain reaction products at 35 cycles from 0.1 g of total RNA from each tissue. Lower lanes (protein) show tissue homogenates (15 g protein) that were subjected to immunoblot analysis with the use of anti-human sPLA 2 -X polyclonal antibody. B, Immunoblot analysis of the peripheral serum (15 L) after ischemia and reperfusion, the supernatant (sup) (15 L) of fMLP-treated neutrophils (1ϫ10 6 cells/mL), and adenosine diphosphate-stimulated platelets (1ϫ10 8 platelets/mL). Recombinant mouse sPLA 2 -X protein (0.2 g) served as a positive control. C, Enzyme-linked immunosorbent assay for sPLA 2 -X in the peripheral serum after ischemia/ reperfusion, in the supernatant of fMLP-treated neutrophils (1ϫ10 6 cells/mL), and in adenosine diphosphate-stimulated platelets (1ϫ10 8 platelets/ mL). The lower detection limit of this enzymelinked immunosorbent assay is 1 pg/mL (nϭ4 in each experiment). n.d. indicates undetectable.
Figure 3.
Immunohistochemical and immunofluorescence microscopic images of hearts from sPLA 2 -X ϩ/ϩ mice. A to D, Immunohistochemical light microscopic images of ischemic myocardium with the use of the anti-human sPLA 2 -X polyclonal antibody (alkaline phosphataselinked red) (A and C) and double-label immunostaining of the same section together with anti-mouse neutrophil polyclonal antibody (blue) (B and D). E to I, Confocal immunofluorescence microscopic images of ischemic myocardium stained with antibodies for sPLA 2 -X (green), neutrophils (red), and ␣-actinin (blue). E, sPLA 2 -X immunoreactivity. F, Double staining for neutrophils and ␣-actinin. G and H, Triple staining for sPLA 2 -X, neutrophils, and ␣-actinin. I, Control staining with antibodies for neutrophils, ␣-actinin, and anti-sPLA 2 -X antibody absorbed with human sPLA 2 -X protein. I shows no immunoreactivity for sPLA 2 -X. Arrowheads indicate localization of sPLA 2 -X immunoreactivity in neutrophils. Same section was used for E, F, and G, and adjacent sections were used for H and I. Scale bars in A to D and E to I were 50 and 20 m, respectively. Sections were representative of 5 mice.
from sPLA 2 -X ϩ/ϩ mice or sPLA 2 -X Ϫ/Ϫ mice were injected into the irradiated sPLA 2 -X ϩ/ϩ mice through the tail vein. The resulting chimeric mice were subjected to the myocardial ischemia/reperfusion experiments in vivo at 6 weeks after the transplantation. For details, see the online-only Data Supplement.
Measurements of mRNA and Protein Expression Levels
Total RNA was extracted from tissues and cells with a Qiagen RNeasy kit and DNase I (Qiagen, Tokyo, Japan). The polymerase chain reaction primers used are listed in Table I in 
Enzyme-Linked Immunosorbent Assay for sPLA 2 -X and Immunostaining of Mouse Hearts
sPLA 2 -X concentrations were measured as described previously. 11 In this assay, the purified recombinant mouse sPLA 2 -X was used as a standard protein that was detectable in the range of 1 pg/mL to 20 ng/mL. The immunostaining was performed by the ABC technique (Vectastain ABC kit, Vector Laboratories, Burlingame, Calif) and a sequential double-labeling method with the use of anti-human sPLA 2 -X polyclonal antibody and anti-mouse neutrophil polyclonal antibody (Cedarlane, Ontario, Canada). 11 For immunofluorescence, a part of the myocardial sections was incubated with the primary antibodies followed by the secondary antibodies. The primary antibodies included anti-␣-actinin antibody (Sigma, Tokyo, Japan), anti-human sPLA 2 -X polyclonal antibody, and anti-mouse neutrophil polyclonal antibody. The secondary antibodies for the immunofluorescence study included Alexa Fluor 488, Alexa Fluor 546, and Alexa Fluor 647 (Invitrogen, Carlsbad, Calif). For details, see the online-only Data Supplement.
Myocardial Ischemia and Reperfusion In Vivo and Assessment of Area at Risk and Infarct Size
The sPLA 2 -X ϩ/ϩ mice, the sPLA 2 -X Ϫ/Ϫ mice, and the chimeric mice were subjected to 1 hour of myocardial ischemia and 24 hours of reperfusion. When the effect of LY374388, a prodrug of LY329722 (an inhibitor of sPLA 2 activity), on myocardial infarct size was examined in the sPLA 2 -X ϩ/ϩ mice, LY374388 or vehicle was administered once intraperitoneally at a dose of 100 mg/kg 1 hour before the ischemia or at the beginning of the reperfusion. For details, see the online-only Data Supplement.
In Vivo Transthoracic Echocardiography
M-mode echocardiography was performed at baseline and after 1 hour of ischemia followed by 24 hours of reperfusion. For details, see the online-only Data Supplement.
Langendorff Experiment
The exercised hearts were mounted on a Langendorff perfusion system at 37°C and perfused with blood-free Krebs-Henseleit buffer. The hearts were subjected to no-flow global normothermic ischemia followed by reperfusion. Parameters of cardiac function were monitored at baseline and during ischemia/reperfusion. Finally, infarct size was measured. For details, see the online-only Data Supplement.
Measurement of Myeloperoxidase Activity and Neutrophil Counts in Infarcted Hearts
The myeloperoxidase assay procedures are similar to methods described in our previous report. 21 Please refer to the online-only Data Supplement.
Preparations of Neutrophils and Platelets and Assays of Neutrophil Functions
Neutrophils were isolated from the peritoneal fluid and the bone marrow. Neutrophil functions, including migration, respiratory burst, elastase release, and AA release, were measured. For details, see the online-only Data Supplement.
Preparation and Culture of Mouse Cardiomyocytes and Effects of Recombinant Mouse sPLA 2 -X Protein on Cultured Mouse Myocardial Cells
Primary cultures of adult mouse cardiomyocytes were prepared by collagenase digestion from the ventricles of 10-to 14-week-old sPLA 2 -X ϩ/ϩ mice. Please refer to the online-only Data Supplement.
Statistical Analysis
Results are expressed as meanϮSEM. Mean values were compared between 2 groups with an unpaired t test; comparisons of means Comparison of myeloperoxidase activity in LV subjected to 1 hour of ischemia followed by 3 hours of reperfusion between sPLA 2 -X ϩ/ϩ and sPLA 2 -X Ϫ/Ϫ mice after pretreatment with or without LY374388, an inhibitor of sPLA 2 activity (nϭ11 in each treatment group). *PϽ0.001. B, Comparison of number of neutrophils accumulated in the ischemic myocardium subjected to 1 hour of ischemia followed by 3 hours of reperfusion between sPLA 2 -X ϩ/ϩ and sPLA 2 -X Ϫ/Ϫ mice after pretreatment with or without LY374388 (nϭ11 in each treatment group). *PϽ0.001. before and after ischemia/reperfusion were made with the paired t test. The comparison among Ն3 groups was performed by 1-way ANOVA with the Scheffé F procedure for post hoc analysis. PϽ0.05 was considered statistically significant.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Generation and Characterization of sPLA 2 -X ؊/؊ Mice We generated mice that lacked sPLA 2 -X on a C57BL/6J background ( Figure I in the online-only Data Supplement). Homozygous sPLA 2 -X Ϫ/Ϫ mice were born at the expected Mendelian frequency. The sPLA 2 -X Ϫ/Ϫ mice were viable, fertile, and appeared healthy. Necropsy and microscopic examination of major tissues revealed no significant pathology in the sPLA 2 -X Ϫ/Ϫ mice. No significant difference was found in body weight, heart size, heart rate, blood pressure, complete blood count, and percentages of neutrophils in peripheral blood and bone marrow between the sPLA 2 -X ϩ/ϩ and sPLA 2 -X Ϫ/Ϫ mice ( Table II in the online-only Data Supplement). Expression levels of mRNA for cPLA 2 , sPLA 2 -V, and PLA 2 -VI in either the myocardium or isolated neutrophils were similar between the sPLA 2 -X ϩ/ϩ and sPLA 2 -X Ϫ/Ϫ mice ( Figure II in the online-only Data Supplement). The sPLA 2 -IIA is naturally disrupted by a frameshift mutation in C57BL/6J background mice. 8
Myocardial Infarct Size and Echocardiography
In ischemia/reperfusion experiments in vivo, the infarct size/area at risk and the infarct size/left ventricular (LV) mass were significantly smaller in the sPLA 2 -X Ϫ/Ϫ mice than in the sPLA 2 -X ϩ/ϩ mice ( Figure 1A) . Echocardiographic parameters at baseline were comparable between the 2 genotypes of mice. Fractional shortening (FS) after myocardial ischemia/ reperfusion injury decreased less in the sPLA 2 -X Ϫ/Ϫ mice than in the sPLA 2 -X ϩ/ϩ mice ( Figure 1B) . The myocardial infarct size was also significantly reduced in the lethally irradiated sPLA 2 -X ϩ/ϩ mice reconstituted with sPLA 2 -X Ϫ/Ϫ bone marrow compared with the irradiated sPLA 2 -X ϩ/ϩ mice reconstituted with sPLA 2 -X ϩ/ϩ bone marrow ( Figure 1C ). However, in Langendorff experiments using isolated hearts and bloodfree perfusion buffer, the infarct size/LV mass and the LV functional parameters after ischemia/reperfusion were comparable between the 2 genotypes of mice ( Figure 1D and Table III in the online-only Data Supplement).
Expression and Serum Concentrations of sPLA 2 -X in sPLA 2 -X ؉/؉ Mice sPLA 2 -X mRNA and protein were expressed in isolated neutrophils, whereas they were not detectable in the shamoperated hearts of sPLA 2 -X ϩ/ϩ mice (Figure 2A) . Immunoblot analysis and enzyme-linked immunosorbent assay showed that sPLA 2 -X was also detectable in the extracellular supernatant of N-formyl-methionyl-leucyl-phenylalanine (fMLP)stimulated neutrophils but neither in the supernatant of adenosine diphosphate-stimulated platelets (Ͻ1 pg/mL) nor in the circulating peripheral serum after myocardial ischemia/ reperfusion (Ͻ1 pg/mL) in sPLA 2 -X ϩ/ϩ mice ( Figure 2B and 2C). Both immunohistochemical light microscopy and confocal fluorescence microscopy showed that the immunoreactivity of sPLA 2 -X was detected in the neutrophils in the ischemic myocardium and in the myocardial area where neutrophils accumulated ( Figure 3 ).
Myeloperoxidase Activity and Number of Neutrophils in Ischemic Myocardium
Increase in myeloperoxidase activity in ischemic myocardium was significantly less in sPLA 2 -X Ϫ/Ϫ mice than in sPLA 2 -X ϩ/ϩ mice ( Figure 4A ). The number of neutrophils in the ischemic myocardium was also less in sPLA 2 -X Ϫ/Ϫ mice than in sPLA 2 -X ϩ/ϩ mice ( Figure 4B ).
Functions of Isolated Neutrophils
Neutrophils isolated from sPLA 2 -X Ϫ/Ϫ mice had a lower respiratory burst and reduced migration in response to C5a or fMLP and less elastase release in response to serum-opsonized zymosan (OZ) than neutrophils from sPLA 2 -X ϩ/ϩ mice ( Figures 5, 6A , and 6B). The respiratory burst and the migration in response to A23187 (2 mol/L) were also reduced in sPLA 2 -X Ϫ/Ϫ neutrophils compared with sPLA 2 -X ϩ/ϩ neutrophils (respiratory burst: 0.51Ϯ0.1 versus 1.1Ϯ0.1 counts [ϫ10 6 ], respectively; nϭ5 in each experiment; Pϭ0.02; migration: 18Ϯ0.2 versus 38Ϯ0.2 neutrophils per high-power field, respectively; nϭ5 in each experiment; Pϭ0.01). However, neutrophil function in response to AA (1 mol/L) and phorbol-12-myristate-13-acetate (PMA) (10 mol/L) was comparable between sPLA 2 -X Ϫ/Ϫ and sPLA 2 -X ϩ/ϩ mice (Figures 5 and 6A) . The attenuated function of sPLA 2 -X Ϫ/Ϫ neutrophils was reversed by the addition of mouse sPLA 2 -X protein (0.1 to 1 ng/mL) ( Figures 5 and 6A) , which alone at these doses did not induce a respiratory burst or migration. The addition of LY329722, an inhibitor of sPLA 2 activity, suppressed sPLA 2 -X ϩ/ϩ neutrophil responses to C5a, fMLP, or OZ (Figures 5, 6A, and 6B ). Neutrophils isolated from bone marrow in sPLA 2 -X Ϫ/Ϫ mice also had a suppressed respiratory burst in response to fMLP compared with those from sPLA 2 -X ϩ/ϩ mice (2.2Ϯ0.1 versus 4.8Ϯ0.2 counts [ϫ10 5 ], respectively; nϭ5 in each experiment; Pϭ0.01). Extracellular release of AA in response to C5a or fMLP was lower in sPLA 2 -X Ϫ/Ϫ neutrophils than in sPLA 2 -X ϩ/ϩ neutrophils ( Figure  6C ). LY329722 suppressed the AA release from sPLA 2 -X ϩ/ϩ neutrophils ( Figure 6C ). Expression levels of mRNA of NADPH oxidase p47 phox and p67 phox , elastase, CD11b/18, and cyclooxygenase-2 were comparable between sPLA 2 -X Ϫ/Ϫ and sPLA 2 -X ϩ/ϩ neutrophils ( Figure III in the onlineonly Data Supplement).
Cytotoxic Effects of Recombinant Mouse sPLA 2 -X Protein on Cultured Mouse Myocardial Cells
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay showed that incubation with sPLA 2 -X protein dose-dependently injured cultured cardiomyocytes, in association with the increase in lactate dehydrogenase (LDH) concentration in the culture medium and the release of AA from the cardiomyocytes (Figure 7A to 7C ). Furthermore, sPLA 2 -X protein aggravated the hypoxic injury of the cultured cardiomyocytes in the lower concentrations of sPLA 2 -X protein ( Figure  7D ). The cytotoxic effect of sPLA 2 -X was comparable between the cultured myocardial cells from sPLA 2 -receptor Ϫ/Ϫ mice and the littermate sPLA 2 -receptor ϩ/ϩ mice ( Figure 7A and 7B) . Moreover, LY329722, an inhibitor of sPLA 2 activity, suppressed the cytotoxic effect of sPLA 2 -X protein ( Figure 7D ).
Effects of LY374388 in sPLA 2 -X ؉/؉ Mice
Both the infarct size/LV mass and the infarct size/area at risk were significantly smaller in the mice treated with LY374388, a prodrug of LY329722, either 1 hour before myocardial ischemia or at the time of reperfusion compared with vehicle-treated mice ( Figure 8A ). In addition, echocardiography showed that LVFS decreased less in LY374388treated than in vehicle-treated mice ( Figure 8B ). Myeloperoxidase activity and number of neutrophils in ischemic myocardium were decreased in LY374388-treated more than in vehicle-treated mice (Figure 4 ).
Discussion
The present study demonstrated that myocardial ischemia/ reperfusion injury was reduced in sPLA 2 -X Ϫ/Ϫ mice. Moreover, myocardial ischemia/reperfusion injury was also reduced in the irradiated sPLA 2 -X ϩ/ϩ mice reconstituted with bone marrow from sPLA 2 -X Ϫ/Ϫ mice. The extent of myocardial ischemia/reperfusion injury was comparable between sPLA 2 -X Ϫ/Ϫ and sPLA 2 -X ϩ/ϩ mice in Langendorff experiments using isolated hearts and blood-free perfusion buffer, supporting the concept that a deficiency in sPLA 2 -X in blood constituents may contribute to the reduction in myocardial ischemia/reperfusion injury in sPLA 2 -X Ϫ/Ϫ mice. The present study showed that sPLA 2 -X was expressed in neutrophils in the ischemic myocardium of sPLA 2 -X ϩ/ϩ mice and that sPLA 2 -X was not expressed in either the sham-operated myocardial tissues or platelets and was undetectable in the circulating peripheral serum in sPLA 2 -X ϩ/ϩ mice. Furthermore, the sPLA 2 -X Ϫ/Ϫ mice had a lower accumulation of neutrophils in ischemic myocardium, and the sPLA 2 -X Ϫ/Ϫ neutrophils had a reduction in cytotoxic activities such as respiratory burst and elastase release. Taken together, the suppression of the migratory and cytotoxic actions of neutrophils may account for the reduction in myocardial ischemia/ reperfusion injury in sPLA 2 -X Ϫ/Ϫ mice. Moreover, the present study showed that the exogenous administration of sPLA 2 -X protein caused cell injury in the cultured cardiomyocytes, suggesting that sPLA 2 -X secreted from the activated neutrophils also might participate in myocardial ischemia/reperfusion injury in a paracrine manner. 20 Therefore, sPLA 2 -X in neutrophils plays an important role in the pathogenesis of myocardial ischemia/reperfusion injury. Various types of PLA 2 have long been implicated to have a crucial role in degradation of membrane phospholipids during myocardial ischemia/reperfusion injury, [17] [18] [19] 22 but the precise subtype of PLA 2 in these phenomena remains undetermined. 23 The present study using sPLA 2 -X-deficient mice reveals a specific role of sPLA 2 -X in myocardial ischemia/reperfusion injury. It has been shown that sPLA 2 -X is also expressed in macrophages. 24 Although the recruited macrophages within the ischemic myocardium mainly contribute to the healing process of the infarcted myocardium, 25 it remains to be determined whether the functions of sPLA 2 -X Ϫ/Ϫ monocytes/ macrophages may also be altered. The intracellular pathways by which sPLA 2 s are involved in the cell activations are complex and are interrelated with multiple intracellular signals [1] [2] [3] 7, [11] [12] [13] ; therefore, the precise mechanisms by which the neutrophil activities in response to the external stimuli, eg, C5a, fMLP, OZ, or A23187, were suppressed in the sPLA 2 -X Ϫ/Ϫ mice remain unclear. However, the present study showed that the neutrophil activities in Figure 7 . Cytotoxic effects of sPLA 2 -X on cultured mouse myocardial cells. Cultured mouse myocardial cells from sPLA 2 -receptor (R) ϩ/ϩ or sPLA 2 -R Ϫ/Ϫ mice (sPLA 2 -X ϩ/ϩ genotype) were treated with mouse sPLA 2 -X protein or PBS as a vehicle for 24 hours. Cell viability was assessed by the reduction in MTT activity (A) and rise in LDH activity (B) in the supernatant medium (nϭ8 in each experiment). The reduction in MTT activity in the treated cells was presented as percentage of untreated control cells. The percentage of LDH release into the medium was calculated by dividing the amount of activity in the medium by the total of activity (medium LDH and cellular LDH). *PϽ0.05 compared with the respective values in vehicle (PBS)-treated cells. In some experiments (C), cultured cardiomyocytes from sPLA 2 -X ϩ/ϩ mice were prelabeled with 0.5 Ci/mL [ 3 H]AA and incubated with mouse sPLA 2 -X protein for 15 minutes, and the radioactivity in the supernatant was measured in a scintillation spectrometer. In some experiments, cells were coincubated together with LY329722 (10 nmol/L). Activity was expressed as the percentage of the total radioactivity incorporated into the cells (nϭ8 in each experiment). *PϽ0.05. D, Effect of lower concentration of mouse sPLA 2 -X protein (10 ng/mL) on cultured cardiomyocytes from sPLA 2 -X ϩ/ϩ mice in the presence of LY329722 (10 nmol/L) or dimethyl sulfoxide as a vehicle in the hypoxic condition. Cell viability was assessed by the reduction in MTT activity. nϭ8 in each experiment. *PϽ0.05.
response to PMA or AA, which are capable of directly stimulating respiratory burst and migration, 26, 27 were not suppressed in sPLA 2 -X Ϫ/Ϫ neutrophils. Furthermore, expression levels of NADPH oxidase p47 phox and p67 phox , elastase, CD11b/18, and cyclooxygenase-2 were comparable between sPLA 2 -X Ϫ/Ϫ and sPLA 2 -X ϩ/ϩ neutrophils. These results suggest that the machinery for respiratory burst and migration seems to be preserved in sPLA 2 -X Ϫ/Ϫ neutrophils. sPLA 2 -X in neutrophils is confined in intracellular granules 13 that secrete their protein contents in response to external stimuli in a cell surface receptor-dependent or -independent manner. The secreted sPLA 2 -X releases AA from the outer surface of the plasma membrane of the activated neutrophils. In addition, sPLA 2 -X prior secretion produces AA in the intracellular space in the stimulated mammalian cells. 28 A number of reports have shown that AA and its lipid metabolites, known as eicosanoids, in turn participate in the further activation of neutrophils after the external stimuli. 13, 29 This positive feedback mechanism may amplify the sequence of cytotoxic activation of neutrophils through free radicals and proteolytic enzymes. These activation mechanisms may be weakened in sPLA 2 -X Ϫ/Ϫ neutrophils.
The present study showed that LY329722 and its prodrug, LY374388, inhibitors of sPLA 2 activity, were capable of reducing myocardial ischemia/reperfusion injury as well as activities of neutrophils. However, these inhibitors are not specific inhibitors of sPLA 2 -X, but they also inhibit other sPLA 2 s such as sPLA 2 -V. Because other sPLA 2 s as well as sPLA 2 -X can also be involved in myocardial ischemia/reperfusion injury, the inhibition of sPLA 2 -X and other sPLA 2 s might be therapeutically useful for acute myocardial infarction. sPLA 2 -X can exert various biological responses by binding to the cell surface sPLA 2 -receptor independently of its enzymatic activity. 24, 30 However, the enzymatic activity seemed to be required for sPLA 2 -X-related myocardial injury and activities of neutrophils on the basis of present experiments using sPLA 2 -receptor Ϫ/Ϫ cardiomyocytes or LY329722, an inhibitor of sPLA 2 activity. Although no previous report indicates species-associated difference in the expression profiles of sPLA 2 -X between humans and mice, sPLA 2 -IIA is expressed in myocardium of humans but not C57BL/6J mice. 8, 9 The species difference in the expression profiles and the activities of some sPLA 2 s should be noted for the translation studies. 2, 3, 5 Previous animal studies showed that the anti-neutrophil interventions did not consistently reduce myocardial infarct size. 31 Furthermore, previous clinical trials 32, 33 showed that monoclonal antibodies to CD11/CD18 failed to reduce myocardial infarct size in patients with acute myocardial infarction. However, the mechanisms of neutrophil activation are very complex, involving multiple signaling pathways, and these negative studies do not necessarily deny the possibility of the translation of the present data to humans because the effects of the anti-neutrophil interventions used in the previous negative studies on the sPLA 2 -X secretion in human neutrophils remain unknown.
The cytotoxic activities of neutrophils play a critical role in ischemia/reperfusion syndromes in other organs as well as myocardium. Therefore, the inhibition of sPLA 2 -X may be also useful for ischemic tissue injury and inflammation. In conclusion, myocardial ischemia/reperfusion injury was attenuated in sPLA 2 -X Ϫ/Ϫ mice partly through the suppression of neutrophil cytotoxic activities. Figure 8 . Effects of LY374388 on infarct size (IS) and echocardiographic LV function after myocardial ischemia/reperfusion in sPLA 2 -X ϩ/ϩ mice. Myocardial ischemia/reperfusion injury was performed as in Figure 1 in the sPLA 2 -X ϩ/ϩ mice. LY374388, an inhibitor of sPLA 2 , was administered intraperitoneally at a dose of 100 mg/kg 1 hour before ischemia or at the time of reperfusion in sPLA 2 -X ϩ/ϩ mice. Myocardial infarct size and echocardiographic LV function were determined as in Figure 1 . A, Myocardial infarct size. B, Echocardiographic LV function (%FS). nϭ8 in each experiment. *PϽ0.05, †PϽ0.05 compared with the respective baseline parameters.
